Skip to main content

LTR PHARMA FPO (ASX: LTP) — Company Overview, News & Financial Data

LTR PHARMA FPO logo
LTP LTR PHARMA FPO
A family-run bakery or artisan workshop owner shaking hands with a relationship banker.
Company profile

LTR PHARMA FPO

About

Explore Australia companies

LTR PHARMA FPO is a clinical-stage biopharmaceutical company focused on improving men's health through the development and commercialisation of fast-acting delivery platforms. The company's lead product candidate, SPONTAN, is a novel intranasal spray formulation of a phosphodiesterase-5 inhibitor designed for the rapid on-demand treatment of erectile dysfunction. Beyond its core intranasal delivery technology, the business expands its men's health portfolio through distribution and commercialisation agreements for approved treatments, including oral testosterone replacement therapies. Based in Australia, the company conducts clinical development, regulatory filings, and commercial partnerships to disrupt traditional oral tablet markets.

Snapshot

Public AUOwnership
-Year founded
1–10Employees
Brisbane, AustraliaHead office
Loading Map...
Global footprint

Operations

All Locations
Brisbane, AU

Products and/or services of LTR PHARMA FPO

  • Erectile Dysfunction Therapeutics: Intranasal vardenafil delivery platform engineered for rapid absorption and onset of action within ten minutes, providing on-demand treatment for erectile dysfunction with reduced systemic exposure compared to oral PDE5 inhibitor tablets.
  • Testosterone Replacement Therapies: Commercialisation and distribution of FDA-approved oral testosterone undecanoate capsules in Australia, offering targeted treatment options for men suffering from testosterone deficiency, low energy, and related metabolic conditions.
  • Special Access Scheme Access: Early patient access program supplying nasal spray formulations directly to qualified healthcare practitioners and eligible patients across Australia under Therapeutic Goods Administration regulatory frameworks prior to full market authorization.
  • Clinical Study Programs: Execution of Phase II pharmacokinetic trials and bioequivalence datasets to support streamlined regulatory submissions, including United States Food and Drug Administration Section 505(b)(2) New Drug Application approval pathways.

LTR PHARMA FPO executive team

  • Mr. Lee RodneExecutive Chairman
  • Mr. Jacques SchipperChief Financial Officer
  • Mr. Peter McLennanChief Operating Officer
  • Prof. Geoffrey A. StrangeChief Medical Officer
  • Mr. Danny ZanardoChief Commercial Officer
  • Mr. David HwangJoint Company Secretary
  • Ms. Elizabeth SpoonerJoint Company Secretary